TENAX THERAPEUTICS, INC. Stockholders Equity

Quick Answer

TENAX THERAPEUTICS, INC. reported Stockholders Equity of $97.07 million for fiscal year 2025.

TENAX THERAPEUTICS, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $97.07M +5.5%
2024 $91.99M +1036.0%
2023 $8.10M +442.4%
2022 $1.49M -64.8%
2021 $4.24M -8.2%
2020 $4.63M +22.6%
2019 $3.77M -68.0%
2018 $11.77M +32.5%
2017 $8.88M -48.2%
2016 $17.14M -71.6%
2015 $60.42M -14.2%
2015 $70.43M -15.0%
2014 $82.86M +4759.9%
2013 -$1.78M -413.8%
2012 -$346.0K +90.7%
2011 -$3.72M -275.1%
2010 $2.13M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $96.21M -1.0% -6.9%
June 30, 2025 $103.33M +1064.2% -5.5%
March 31, 2025 $109.29M +779.3% +18.8%
December 31, 2024 $91.99M +1036.0% -5.4%
September 30, 2024 $97.22M +761.4% +995.3%
June 30, 2024 $8.88M -32.9% -28.6%
March 31, 2024 $12.43M -12.9% +53.5%
December 31, 2023 $8.10M +442.5% -28.3%
  • TENAX THERAPEUTICS, INC. showed an increase of +5.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2010–2025 period, TENAX THERAPEUTICS, INC.’s stockholders equity has grown by 4463.7% (from $2.13 million to $97.07 million).
  • The most recent figure is from TENAX THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment